MediciNova, Inc.
MediciNova develops small molecule therapeutics for serious diseases with unmet medical needs. Its focusing on MN-166 for neurological disorders like MS, ALS, and substance dependence, as well as other conditions. The company also has MN-221 for asthma exacerbations, MN-001 for fibrotic diseases, and MN-029 for solid tumor cancers.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 8.1% in each of the last 6 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Small company (enterprise value $41 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data